Market Herald logo

Subscribe

Be the first with the news that moves the market
  • InterCure (INCR.U) announced record preliminary financial results for Q2 2022
  • Record revenue is estimated to be C$36 million, more than double the revenues of Q2 of 2021 and representing sequential growth of over 9 per cent
  • During the quarter, the company saw demand for branded products under its Canndoc subsidiary, expansion of its medical cannabis dispensing operations, and the opening of the first flagship Cookies retail location in Austria, located in the centre of Vienna
  • The company also expanded its medical cannabis dedicated pharmacy chain with the grand opening of its flagship Cookies branded pharmacy in Be’er Sheva, the largest city in Israel’s southern region
  • Intercure Ltd. (INCR.U) was holding steady at C$6.05 per share at 10:00 am ET

InterCure (INCR.U) has announced record preliminary financial results for Q2 2022.

Record revenue is estimated to be C$36 million, more than double the revenues of Q2 of 2021 and representing sequential growth of over 9 per cent.

During the quarter, the company saw demand for branded products under its Canndoc subsidiary, expansion of its medical cannabis dispensing operations, and the opening of the first flagship Cookies retail location in Austria, located in the centre of Vienna.

The company also expanded its medical cannabis dedicated pharmacy chain with the grand opening of its flagship Cookies branded pharmacy in Be’er Sheva, the largest city in Israel’s southern region.

InterCure’s Chief Executive Officer Alexander Rabinovitch credited his team’s solid operating performance in Q2, as the key that led the business to its 10th consecutive quarter of profitable growth, representing an annualized run rate of C$143 million.

“InterCure is focused on developing and launching the world’s leading pharmaceutical grade medical cannabis products in parallel to the global expansion of our production and distribution platform. InterCure’s target markets are evolving at a rapid pace as more and more countries adopt supportive regulations that allow us to operate and implement our leading model.”

The company plans to file its full financial results for Q2 on Monday, August 15, 2022, and expects continued increases in revenues during Q3 2022.

InterCure engages in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. The products are distributed to hospitals, pharmacies, research, and government organizations.

The company leverages its market-leading distribution network, best-in-class international partnerships and a high-margin vertically integrated “seed-to-sale” model to lead the fastest growing cannabis global market outside North America.

InterCure Ltd. (INCR.U) was holding steady at C$6.05 per share at 10:00 am ET.

More From The Market Herald
Emerald Health Therapeutics Inc. - Director & Chairman, Jim Heppell.

" Emerald Health (CSE:EMH) shareholders approve merger

Emerald Health Therapeutics (EMH), has received shareholders’ approval for the proposed plan of arrangement with Skye Bioscience Inc.
Mydecine Innovations Group - CEO, Josh Bartch.

" Mydecine (NEO:MYCO) raises $244K and shifts management team

Mydecine Innovations Group (MYCO) has signed a common share subscription agreement with a third-party investor for proceeds up to $244,99.50.

" Verano (CSE:VRNO) announces the opening of Zen Leaf Clarksburg

Verano Holdings (VRNO) has announced the opening of Zen Leaf Clarksburg, its fourth dispensary in West Virginia and 111th nationwide.
PharmaDrug - CEO, Daniel Cohen

" PharmaDrug (CSE:PHRX) completes milestone to support cGMP production of PD-001

PharmaDrug (PHRX) has laid the groundwork to support cGMP production of cepharanthine-2HCL for use in the drug product production of PD-001.